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Abstract
DNA microarray based gene expression analysis of primary breast
cancers is not in general clinical use in spite of the widespread
enthusiasm for the approach. However, several studies have
identified gene expression patterns, or “signatures” that are
predictive of disease outcome and assays based on these findings
have become commercially available. Additional studies are
required to further define gene signatures that can be used to help
tailor the therapy best suited to for an individual patient. Recent
gene expression profiling studies using cell line models to identify
downstream transcriptional targets of oncogenic signaling path-
ways may help achieve this goal.
Gene expression profiling of cancers has great potential as a
valuable tool in the identification of new clinical biomarkers
and of the molecular pathways that underlie the disease.
Among other factors, expression profiling may uncover new
molecular subtypes of breast cancer that transcend current
histologic definitions. In a series of seminal studies conduc-
ted by Sorlie and coworkers [1], hierarchical clustering of
breast tumor profiles from multiple independent datasets
revealed a basal epithelial-like group, an ERBB2/HER2-
overexpressing group, two distinct luminal-like groups, and a
normal breast-like group. However, current histologic
definitions of breast cancer largely reflect the tumor subtypes
uncovered by Sorlie and colleagues; for instance, the basal
tumors reflect the estrogen receptor (ER)-negative subtype,
whereas the luminal tumors reflect the ER-positive subtype. It
would be useful to know whether additional relevant subtypes
of breast cancer may be uncovered, either by profiling larger
cohorts of tumors or by using alternative data analysis
approaches, with the ultimate goal of individualizing therapy
based on the molecular profile of the patient’s tumor. There is
already established precedence for clinical use of molecular
markers to help make decisions on the course of treatment in
breast cancer, because expression of ER and progesterone
receptor are used to assess the potential response to
hormonal therapy, and expression of ERBB2/HER2 is used to
assess potential response to herceptin.
A number of studies have identified gene expression patterns
in breast cancer with the ability to predict disease outcome.
The first of these studies is that by van ’t Veer and coworkers
[2], in which a classifier of 70 genes was defined that
outperformed all clinical variables in predicting the likelihood
of distant metastases within 5 years. Van ’t Veer and
colleagues have formed a cancer diagnostics company [3],
which provides a service called MammaPrint to assess
recurrence risk in breast cancer patients using cDNA
microarrays to profile the 70-gene set. The service is
intended to assist in ensuring that those patients who are at
high risk for metastases receive additional therapy designed
to reduce the chance of disease recurrence. In addition, the
MammaPrint service is intended to identify and spare low risk
patients from receiving unnecessary chemotherapy, avoiding
unnecessary costs and potentially serious side effects. The
clinical utility of Mammaprint is being tested in a prospective
phase III study (MINDACT); however, the utility and
effectiveness of the test will not be known for many years.
Although much enthusiasm initially surrounded the profiling
studies from van ’t Veer and others, a substantial amount of
skepticism has since emerged in the breast cancer
community regarding whether gene signatures predictive of
breast cancer outcome will eventually be incorporated into
clinical breast cancer decision making. One set of issues
surrounds statistical concerns that prognostic gene
signatures such as the van ’t Veer 70-gene set were
developed using training datasets representing a single
cohort of a relatively small number of patients, and so
therefore they may not be universally applicable to breast
cancer patients. Additionally, some of the prognostic gene
signatures derived for various cancers were ‘validated’ on
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subsets of the same patient cohort used to generate the
given signature. Furthermore, gene expression profiling
studies of breast cancer subsequent to that of van ’t Veer and
coworkers have derived top sets of prognostic markers that
differ somewhat from the 70-gene set; in our opinion,
however, this last issue does not point to any inconsistency in
independently obtained results but rather to the fact that the
entire population of genes correlated with patient survival
may be quite large. At the same time, one could argue that
the 70-gene set, for example, may not necessarily represent
the ‘best’ or optimal set of predictors, and many have
advocated using training datasets of thousands, rather than
tens, of patient profiles for developing more robust prog-
nostic signatures. Importantly, many signatures such as the
van ’t Veer signature have been shown to be prognostic in
multiple microarray datasets from independent studies,
although the predictive power, while statistically significant,
has not been as impressive in terms of a hazard ratio in
subsequent datasets.
Aside from statistics related issues, another issue with
applying results of gene expression profiling studies to the
clinic pertains to the distinction between general prognosis
and therapeutic prediction. The gene signatures correlated
with survival arising from previous profiling studies appear to
be prognostic – that is, they indicate whether or not a patient
will have a good outcome – but they do not necessarily
predict how a patient will respond to a given course of
adjuvant treatment. There is a need to develop gene
signatures that may help in planning regimens of adjuvant
therapy that are best suited to each particular patient.
Where the MammaPrint assay was designed for assessing
prognosis in breast cancers, the commercially available
Oncotype DX gene assay [4] was originally designed and
extensively validated for predicting response to tamoxifen
therapy in ER-positive breast cancer patients. The assay
measures the expression levels of 21 genes by RT-PCR of
RNA from paraffin-embedded tissues. As described in the
study by Paik and coworkers [5], the 21 genes, 16 of which
are cancer related and the other five of which are reference
genes, were prospectively selected using the biomedical
literature, gene expression array datasets, and RT-PCR
assays of multiple independent clinical cohorts. The Onco-
type DX assay has a distinct advantage over the MammaPrint
assay in being able to use paraffin-embedded tissues,
thereby having no extra requirements for tumor RNA sample
procurement. Recently, Medicare agreed to cover the costs
of Oncotype DX beginning late February of 2006. Oncotype
DX has recently been shown not only to predict response to
tamoxifen but also to indicate prognosis in untreated patients.
In addition to using gene expression profiling to assess the
potential overall response to therapy, tumor profiling may
predict response to neoadjuvant therapy, as demonstrated in
a study by Chang and coworkers [6]. In this study, core
biopsy samples were taken from primary breast tumours in 24
patients before treatment with four cycles of docetaxel over
3 weeks. The samples were profiled and the expression
pattern of 92 genes found to distinguish responsive verses
nonresponsive tumors. We believe that this approach could
be expanded to include additional therapies with the ultimate
goal of classifying cancers into ‘therapeutic responsive’
groups instead of the current ‘pathological’ groups.
Identifying patients who are likely to respond to a particular
therapy before treatment will help to minimize some of the
unavoidable trial and errors currently associated with clinical
oncology. In the case of molecular targeted therapies such as
tamoxifen or herceptin, it may be possible to determine
whether the therapy is having any impact on the pathway of
interest, as ‘oncogenic mRNA signatures’ (described below)
of signaling pathways such as ER or HER2 become available.
In order to develop more effective treatments for breast
cancer, we need a better understanding of the molecular
pathways that underlie the development and progression of
the disease. RNA expression profiling studies have
uncovered hundreds of genes with correlations with clinical
parameters such as ER status or patient outcome. However,
to make sense of the bigger picture of breast cancer at a
molecular level, we need to be able to associate the genes
with the various pathways they represent. Although molecular
biology has made great strides in the past 30 years in
uncovering, at the signal transduction level, the oncogenic
pathways on which different cancers rely, until recently we
have had an incomplete understanding of what many of these
pathways ‘look’ like at level of gene transcription. Numerous
studies are now being published in which a given signaling
pathway of interest is manipulated in cell culture or mouse
models, in order to identify the downstream transcriptional
targets of the pathway by expression profiling. With the data
from these experiments being made publicly available, further
studies could integrate these pathway mRNA signature data
with breast tumor profile data in meaningful ways.
A recent study by Bild and coworkers [7] highlights how
gene signatures of oncogenic pathways can be used to
identify patterns of pathway deregulation in breast cancer
cells, with implications for guiding targeted therapies. Using
human primary mammary epithelial cell cultures and
recombinant adenoviruses, those investigators activated the
oncogenic pathways of Myc, Ras, E2F3, Src, and β-catenin.
Using gene expression profiles of these cell culture experi-
ments, human breast tumor profiles could be separated, on
the basis of which pathways appeared to be activated, into
categories relevant to clinical outcome. Furthermore, in a
panel of breast cancer cell lines, the sensitivity of a given cell
line to Ras pathway inhibitors could be predicted on the basis
of whether the profile of the cell line shared similarities to the
Ras oncogenic signature. This study further indicates that we
may be approaching a time when, given an expression profile
from a patient’s tumor, we could make an accuratePage 3 of 3
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assessment in the clinic of which pathways would be best to
target in that patient.
In conclusion, we believe that gene expression profiling will
have increasing impact in the clinic over the next several
years, in terms of our being better able to assess the risk of
recurrence in breast cancer patients, to predict patient
response to neoadjuvant therapy, to assess which oncogenic
pathways are deregulated in a given tumor as a guide for
targeted adjuvant therapy, and to develop better targeted
therapies as our understanding of the molecular biology of
breast cancers improves.
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